GlassScriptPhysician profile
Julien Feghaly
NPI 1356847651
$6,447.71
in general payments reported to CMS, 2019-2025
9 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $510 · 2023: $1,017 · 2024: $4,335 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $3,294 · Food and Beverage: $1,503 · Travel and Lodging: $530 · Education: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $3,294.12 |
| Food and Beverage | $1,503.42 |
| Travel and Lodging | $530.08 |
| Education | $399.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,385.23 | 2023-2024 | Onyx Frontier, Corevalve Evolut R |
| Abbott Laboratories | $1,269.35 | 2021-2025 | Ensite, Navitor, Xience Skypoint |
| Abiomed | $627.30 | 2022-2025 | Impella |
| Boston Scientific Corporation | $453.83 | 2023-2024 | |
| Penumbra, INC. | $264.77 | 2024 | Indigo System |
| Astrazeneca Pharmaceuticals LP | $135.00 | 2025 | |
| Inari Medical, INC. | $122.18 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Philips North America LLC | $119.76 | 2023 | (9266) Elca |
| Chiesi USA, INC. | $70.29 | 2024 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julien Feghaly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.